Weight gain (hormonal)
Medically reviewed by Hormone Journal Editorial Team · Last reviewed 2026-05-22
Hormonal weight gain is unexplained body-weight increase driven by thyroid dysfunction, insulin resistance, cortisol excess, or reproductive hormone imbalances rather than diet alone.
What it is
Hormonal weight gain is unexplained body-weight increase driven by thyroid dysfunction, insulin resistance, cortisol excess, or reproductive hormone imbalances — conditions that affect an estimated 1 in 5 Canadian adults at some point in their lives. Also called endocrine-related or metabolically driven weight gain, this term describes situations where the hormonal system, rather than simple caloric excess, is the primary engine behind fat accumulation or redistribution.
All weight gain ultimately reflects an energy imbalance, but hormones regulate appetite, fat storage, metabolic rate, and body composition in ways that can make weight gain far easier and weight loss far harder — even when a person is eating and exercising appropriately. Hormonally driven weight gain often has distinctive features: it concentrates in specific body areas, appears alongside other hormonal symptoms, and resists conventional dietary and exercise interventions until the underlying cause is identified and treated. This page focuses specifically on hormonal contributors, which are frequently overlooked in standard clinical workups.
Causes and mechanism
Several hormonal pathways can independently or jointly drive weight gain:
Thyroid dysfunction — Hypothyroidism (underactive thyroid) reduces basal metabolic rate, lowering caloric expenditure and causing fluid retention. It is one of the most common and most frequently missed hormonal causes of unexplained weight gain, affecting roughly 2–3% of Canadians, with women affected 5–10 times more often than men.
Insulin resistance and related conditions — Insulin resistance promotes visceral (abdominal) fat storage and impairs fat burning. It is central to weight gain in polycystic ovary syndrome (PCOS), metabolic syndrome, and prediabetes. PCOS — a condition affecting approximately 8–13% of reproductive-age women — combines insulin resistance with elevated androgens, driving central weight gain and making loss particularly difficult.
Adrenal hormones — Cortisol excess, whether from Cushing's syndrome or chronic psychological stress, promotes fat deposition in the abdomen, face, and upper back. Even sub-clinical cortisol dysregulation from sustained stress can contribute meaningfully to central adiposity.
Reproductive hormones — The following table summarizes the main reproductive-hormone contributors:
| Hormone change | Mechanism | Typical fat pattern |
|---|---|---|
| Estrogen decline (menopause) | Shifts fat from hips/thighs to abdomen; slows metabolic rate | Central/visceral |
| Progesterone deficiency | Fluid retention, reduced insulin sensitivity | Generalized bloating |
| Low testosterone (men) | Reduced lean mass, lower resting metabolism | Central, with muscle loss |
Other contributors — Growth hormone deficiency increases body fat and reduces lean mass. Leptin resistance causes the satiety signal to lose effectiveness, driving overconsumption. Several commonly prescribed medications — including corticosteroids, some antidepressants, antipsychotics, and certain diabetes drugs — also cause clinically significant weight gain.
Symptoms and diagnosis
The pattern of weight distribution often points toward the underlying cause before any bloodwork is ordered:
- Central/abdominal gain — insulin resistance, cortisol excess, post-menopausal estrogen decline
- Face, neck, upper back — Cushing's syndrome
- Hips, thighs, breast tenderness, bloating — estrogen dominance or progesterone deficiency
- Generalized puffiness — hypothyroidism
Associated symptoms matter equally. Fatigue, cold intolerance, dry skin, and constipation point toward hypothyroidism. Irregular periods, excess facial hair, and acne suggest PCOS. Hot flashes and vaginal dryness indicate menopause. Anxiety, sleep disruption, and elevated blood pressure raise concern for cortisol excess. Reduced muscle mass, low libido, and low mood are consistent with hypogonadism in men.
A standard hormonal evaluation typically includes:
- TSH and thyroid panel — first-line for unexplained weight gain
- Fasting glucose, HbA1c, and fasting insulin (HOMA-IR) — to assess insulin resistance
- Lipid panel — to identify metabolic dyslipidaemia
- Sex hormones (testosterone, estradiol, FSH, LH, SHBG) — to evaluate menopausal status, PCOS, or hypogonadism
- Morning serum cortisol or 24-hour urinary free cortisol — if Cushing's syndrome is suspected
- IGF-1 — if growth hormone deficiency is suspected
- Waist circumference and body composition assessment
In Canada, most of these tests are available through provincial health plans and can be ordered by a family physician. LifeLabs and Dynacare both process the full panel in most provinces.
Treatment options
Treatment targets the underlying hormonal cause alongside lifestyle optimization — neither alone is usually sufficient.
Correcting the hormonal driver:
- Hypothyroidism: levothyroxine replacement typically produces 2–4 kg of weight loss from fluid and metabolic normalization, though it rarely resolves significant obesity on its own.
- PCOS and insulin resistance: metformin, GLP-1 receptor agonists (semaglutide, liraglutide), and carbohydrate-modified diets targeting insulin sensitivity.
- Menopause: menopausal hormone therapy (MHT) can attenuate the post-menopausal shift toward central adiposity and support weight management; the SOGC's 2021 menopause guideline supports MHT for appropriate candidates.
- Low testosterone in men: testosterone replacement therapy improves body composition by increasing lean mass and reducing fat, with the greatest benefit when combined with resistance training.
- Cushing's syndrome: treating the cortisol source leads to gradual weight loss over months.
Lifestyle interventions (essential alongside hormonal treatment):
- Reducing refined carbohydrates and prioritizing protein and fibre improves insulin response and satiety.
- Both aerobic exercise and resistance training improve insulin sensitivity and preserve lean mass; Canadian guidelines recommend at least 150 minutes of moderate-intensity activity per week.
- Consistently achieving 7–9 hours of sleep restores leptin-ghrelin balance and improves insulin sensitivity.
- Targeted stress reduction directly lowers cortisol and supports weight management.
Pharmacological weight management: GLP-1 receptor agonists are effective across many hormonally driven weight conditions, including PCOS, insulin resistance, and metabolic syndrome. In Canada, semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda) are available, though coverage varies by province and indication.
When to see a clinician in Canada
Seek assessment if you experience unexplained weight gain of more than 2–3 kg over weeks to months without a clear dietary explanation, particularly if it is accompanied by fatigue, cold intolerance, irregular periods, excess hair growth, mood changes, or sleep disruption. Persistent difficulty losing weight despite genuine dietary and exercise effort also warrants investigation. Weight concentrated in the abdomen, face, or upper back — especially with other symptoms suggesting cortisol excess — should be evaluated promptly.
A family physician can order first-line hormonal bloodwork and refer to an endocrinologist if needed. Canadians in provinces with limited specialist access can also consult through virtual care platforms such as Felix, Maple, Cleo, or Phoenix, several of which offer hormone-focused assessments.
Limitations and open questions
Research is still emerging on the relative contribution of sub-clinical hormonal changes — such as mild cortisol dysregulation from chronic stress or low-normal thyroid function — to weight gain in the general population. The threshold at which these changes become clinically meaningful is not firmly established. Evidence on whether treating borderline hormonal abnormalities produces meaningful weight loss is mixed, and most trials are short-term. Health Canada has not yet issued specific guidance on using GLP-1 receptor agonists for hormonally driven weight gain outside of type 2 diabetes and general obesity indications. The interaction between multiple simultaneous hormonal disruptions (e.g., menopause plus insulin resistance) is understudied. Clinicians and patients should weigh individual risk-benefit profiles carefully rather than treating lab values in isolation.
FAQs
Can thyroid problems cause weight gain?
Yes. Hypothyroidism — a condition in which the thyroid gland produces insufficient thyroid hormone — reduces basal metabolic rate and causes fluid retention, typically producing weight gain of 2–5 kg. The gain is partly metabolic and partly from fluid accumulation, not primarily from increased fat. Treating hypothyroidism with levothyroxine usually results in partial reversal of this weight gain, though it rarely resolves significant obesity on its own if other contributing factors are present.
Does menopause cause weight gain?
Menopause does not inevitably cause overall weight gain, but it does reliably change where the body stores fat. The loss of estrogen shifts fat distribution from the hips and thighs toward the abdomen, increasing visceral fat even when total weight stays the same. According to Mayo Clinic data, weight gain during the perimenopausal years continues at roughly 1.5 pounds (0.7 kg) per year through a woman's 50s, driven more by age-related metabolic slowdown and lifestyle factors than by menopause alone. This central fat is metabolically more harmful and raises cardiovascular and metabolic risk.
Can stress really cause weight gain?
Yes. Chronic stress raises cortisol levels, and cortisol promotes visceral fat accumulation, increases appetite — particularly for high-calorie foods — raises blood glucose, and opposes insulin's effects. Research published in PMC (Schwarz et al., 2011) confirms that perceived stress and elevated cortisol are independently associated with weight gain. Stress also disrupts sleep and reduces physical activity, compounding its metabolic effects. For many people, addressing chronic stress is as important as diet and exercise in managing weight.
If my weight gain is hormonal, will treating the hormone fix the weight?
Treating the underlying hormonal cause typically helps but rarely produces dramatic or complete weight loss on its own. Levothyroxine for hypothyroidism may result in 2–4 kg of weight loss. Testosterone replacement in hypogonadal men improves body composition but requires resistance training to maximize muscle gain. Menopausal hormone therapy reduces central fat accumulation but does not reverse significant pre-existing obesity. In most cases, hormonal treatment creates a more favourable metabolic environment in which lifestyle interventions become significantly more effective.
Is hormonal weight gain testing covered by provincial health plans in Canada?
Most first-line hormonal investigations — including TSH, fasting glucose, HbA1c, lipid panel, and basic sex hormone panels — are covered under provincial health insurance when ordered by a physician for a clinical indication. More specialized tests such as 24-hour urinary cortisol or IGF-1 may require specialist referral for coverage in some provinces. GLP-1 receptor agonists for weight management are not universally covered; coverage varies by province and by whether a diagnosis of type 2 diabetes or obesity is documented. Checking your provincial formulary or speaking with a pharmacist is the most reliable way to confirm current coverage.
Sources
- Hypothyroidism and obesity: An intriguing link — Indian Journal of Endocrinology and Metabolism
- Understanding weight gain at menopause — Climacteric (PubMed)
- Obesity, Dietary Patterns, and Hormonal Balance Modulation — Nutrients (PMC)
- A Review of Weight Control Strategies and Their Effects on the Regulation of Hormonal Balance — Journal of Nutrition and Metabolism (PMC)
- Menopause weight gain — Mayo Clinic
- Menopause: Vasomotor Symptoms, Prescription Therapies, and Non-Hormonal Options — SOGC Clinical Practice Guideline